Authors for correspondence:
Xiang-Yang Ye
e-mail: xyye@hznu.edu.cn
Tian Xie
e-mail: xbs@hznu.edu.cn

ROYAL SOCIETY OF CHEMISTRY

THE ROYAL SOCIETY PUBLISHING

β-Elemene derivatives produced from SeO₂-mediated oxidation reaction

Xingrui He[1,2,3,4,†], Xiao-Tao Zhuo[1,2,3,†], Yuan Gao[5], Renren Bai[6], Xiang-Yang Ye[1,2,3,7] and Tian Xie[1,2,3,7]

[1]Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province,
[2]Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, and [3]Holistic Integrative Pharmacy Institutes (HIPI),
School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang 311121, People's Republic of China
[4]School of Pharmacy, Liaocheng University, Shandong 252000, People's Republic of China
[5]School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510000, People's Republic of China
[6]College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, People's Republic of China
[7]Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, People's Republic of China

XH, 0000-0002-7591-8022; X-TZ, 0000-0002-4388-4809;
YG, 0000-0003-2254-6381; RB, 0000-0002-3511-5794;
X-YY, 0000-0003-3739-0930; TX, 0000-0001-7066-1443

Herein, we report the first access of β-elemene derivatives through the SeO₂-mediated oxidation reaction. Several new compounds were isolated through such a one-step reaction, and their structures were elucidated using various 2D-NMR techniques. This method provides easy access to multiple oxidative β-elemene derivatives in one single step and represents the first modifications on cyclohexyl ring of β-elemene. It is expected to open up the opportunity for future derivatization on cyclohexyl ring of β-elemene. The new compounds obtained above showed better anti-proliferation activities than β-elemene itself on several cancer cell lines. Among them, compound **17** shows the best activity in antiproliferation assays of A549 and U-87MG cell lines.

1. Introduction

The plant *Curcuma wenyujin* Y. H. Chen et C. Ling belongs to one of the important traditional Chinese medicines (TCM), and has been used to treat cancer and various diseases for nearly a thousand years [1–4]. The essential oil obtained from this plant is called elemene extracts, which contain at least four sesquiterpene isomers, namely α-elemene, β-elemene (**1**),

Figure 1. (*a*) The structure of β-elemene with carbon atoms numbering; (*b*) the ground-state chair conformation of β-elemene [18]. The two hydrogen atoms on C-2 and C-4 are theoretically accessible to SeO$_2$-mediated allylic oxidation besides C-13 and C-14.

γ-elemene, and δ-elemene [5–7]. In 2008, the State Food and Drug Administration of China approved the uses of elemene extracts in two special dose forms: liposomal oral liquids (for treatment of oesophageal and gastric cancers) and liposomal injections (to treat leukemia, brain, breast, ovarian and lung cancers) [8,9]. In the past two decades, numerous papers and patents published in China and across the world established the clinical usefulness of elemene extracts as a wide spectrum anti-cancer drug [10–16]. The mechanism of action of elemene is yet to be uncovered.

Within the four major sesquiterpene isomers, β-elemene is reported to be the major isomer, consisting of 40–80% of elemene extracts depending on the isolation and purification process [17]. It is undoubted that β-elemene is the major pharmacology contributor among the four isomers. Other isomers (α-elemene, γ-elemene and δ-elemene) might also contribute to the anti-cancer effects to some extent, which is another topic of interest under our investigation.

β-Elemene, named (5S,7R,10S)-(-)-(1-methyl-1-vinyl-2,4-diisopropenyl-cyclohexane), contains only hydrogen and carbon elements (figure 1). The biological activity of β-elemene is moderate or weak, indicated by its high IC$_{50}$ value against several tumour cell lines [19,20]. Barrero *et al.* reported the synthesis of β-elemene from germacrone in several steps [21]. In recent years, several papers have been published regarding the modifications of β-elemene, in the hope to seek better biological activity and to improve its water solubility [22–26]. The modifications of β-elemene described thus far are limited to two positions: C-13 and C-14. Such limitations are largely due to the stereoelectronic preference for reaction at C-13 and C-14. Herein, we report that SeO$_2$-mediated oxidation conditions can yield other oxidation patterns.

β-Elemene possesses three carbon-carbon double bonds, all connected to the cyclohexyl skeleton. These three C=C bonds are all terminal double bonds, two of them being di-substituted and one being mono-substituted. Conformational analysis of β-elemene suggests these three alkene substituents are probably positioned equatorial in ground state. Furthermore, C-14 is more sterically hindered than C-13 due to its proximity to the C-15 quaternary centre. Similarly, the proton on C-2 is slightly more hindered than the proton on C-4. The steric effects analysed above agree well with what Thomas *et al.* described in their epoxidation of β-elemene double bond [27].

Selenium dioxide (SeO$_2$)-mediated allylic oxidation of olefin to allylic alcohol, commonly known as Riley oxidation, is one of the most important transformations in organic synthesis [28,29]. Typically, an olefin is subjected to a catalytic SeO$_2$ and stoichiometric tert-butylhydroperoxide (TBHP) under mild conditions. Since its discovery, the Riley oxidation has been widely applied in organic synthesis [30,31]. The mechanism of Riley oxidation and the preferences and selectivity of reaction sites of the allylic group were well documented in the literature [32,33]. Preference (region- and chemoselectivity) will be dictated by stereoelectronics. In the case of β-elemene, there are four different allylic protons, namely protons at C-2, C-4, C-13 and C-14, respectively. Our interests in modifying unexplored positions of β-elemene prompt us to examine the SeO$_2$-TBHP condition on this substrate. Of all the four hydrogen-bearing allylic carbons, C-2 and C-4 draw our attention. We envision that the SeO$_2$-mediated oxidation reaction might access the hydrogen atoms on these two carbons, in addition to C-13 and C-14, and hence, might install the hydroxyl group on these two positions of cyclohexyl ring. As a result, the modification products of β-elemene on its cyclohexyl ring could be obtained. Those modifications on the cyclohexyl ring of β-elemene represent the synthetic challenge to date. Additionally, SeO$_2$-mediated allylic oxidation will also generate the oxidative products from C-13 and C-14 (plus the possible combination). These products, though previously reported, can only be synthesized in several steps [24,25,34–37] (figure 2).

Figure 2. Summary of the allylic oxidation of β-elemene.

2. Results

β-Elemene raw material is the gift from Holley Kingkong Pharmaceutical Co., Ltd. GC-MS analysis[1] suggests that it contains only about 78% of β-isomer, plus the other three isomers. Since the four elemene isomers possess very similar structure and physical properties, to purify them in the laboratory represents a challenge. Therefore, the material was used as-is. Understandably, the presence of other isomers will generally give lower yield as well as complicate the isolation process.

β-Elemene raw material was subjected to a SeO_2-mediated oxidation reaction in CH_2Cl_2, with 5 equivalent of TBHP at 0°C for 6 h. After standard work-up process, the crude product was purified in silica gel chromatography (petroleum ether (PE)/ethyl acetate (EA)) to yield four fractions, with polarity from the least to the most: fraction **I** ($R_f = 0.9$, PE/EA = 4:1, 7.4% yield), fraction **II** ($R_f = 0.7$, PE/EA = 4:1, 2.8% yield), fraction **III** ($R_f = 0.2$, PE/EA = 4:1, 8.6% yield) and fraction **IV** ($R_f = 0.15$, PE/EA = 4:1, 21.6% yield) (Scheme 1).

The above four fractions were analysed by HPLC. The results revealed that only fraction **IV** contains a single compound, the other three fractions were all mixtures of two compounds.

Fraction **I** appears to be a single spot in TLC (petroleum-ethyl acetate system). After screening with several mix solvent systems for TLC, petroleum ether/acetone system was found to be the best solvent to resolve the two compounds (Scheme 2). The structure of compound **2** was established by NMR in comparison with references [35]. The structure of compound **3** was elucidated through various 2D NMR techniques (see electronic supplementary material for details). It should be noted that compound **2** was synthesized in the literature involving three steps and a tedious HPLC purification process [35].

The ^{1}H NMR of fraction **II** reveals two sets of signals in about 1 to 1 ratio, containing both aldehyde proton and allylic protons connecting to a hydroxyl group, presumably from compounds **6** and **7**. Attempt to resolve them in TLC using a variety of mix solvent systems (similar to fraction **I**) was proven to be unsuccessful. We then turned to protecting group strategy. Thus, 50 mg of fraction **II** was treated with TBDMS-Cl/imidazole to install TBDMS group on hydroxyl groups, resulting in two compounds **4** and **5**, which were carefully separated in silica gel chromatography. The isolation yield

---

[1]GC-MS analysis was performed in Agilent Technologies 7890B (GC system) and 5977A MSD (Mass unit) under the following conditions: Agilent gas chromatograph and gas work station, FID detector, capillary chromatography (Agilent 19091S-433UI, HP-5 ms Ultra Inert, 60–325°C, 30 m × 250 mm × 0.25 mm); injection temperature: 250°C, detector temperature: 230°C, rise range: starting temperature: 50°C, maintain for 2 min, rise to 80°C at the rate of 20°C per minute, maintained for 2 min, then increased to 150°C at the rate of 30°C per minute, maintained for 5 min; carrier gas: helium, flow rate: 24.2 ml min^{-1}, chromatographic column flow rate: 1.2 ml min^{-1}, pressure: 9.8 psi, tail gas flow rate: 3 ml min^{-1}, injection volume: 1 ml, split ratio: 100 : 1. The retention time of β-elemene is 9.05 min under the above conditions.

Scheme 1. Synthesis of β-elemene derivatives via SeO$_2$-mediated oxidation reaction.

Scheme 2. Compounds **2** and **3** were resolved in silica gel chromatography using petroleum ether/acetone mixed solvent.

is low because these two compounds are close to each other and the majority material stays as a mixture. If necessary, the mixture can be subjected to chromatography repeatedly to give a better yield of pure **4** and **5**. After standard deprotection of tert-butyldimethylsilyl group, compounds **6** and **7** were obtained respectively. The structures of **6** and **7** were established by NMR. Alternatively, compounds **6** and **7** might be separated using a suitable column in the preparative HPLC system (Scheme 3).

The ^{1}H NMR of fraction **III** did not show the aldehyde proton signal. Therefore, the mixture presumably contains allylic alcohols. After screening a set of mixed solvent systems for TLC, dichloromethane/acetone (1:1 v/v) appears to give the best resolution. Thus compounds **8** and **9** were obtained in about 3 to 2 ratio, and their structures were established via various 2D NMR techniques (Scheme 4) [36].

The analysis by HPLC and ^{1}H NMR of fraction **IV** indicates it is a single compound, whose structure was established as compound **10** by comparing its ^{1}H NMR with known compound 13,14-bis(hydroxyl)-β-elemene [9,38,39]. Compound **10** is a known compound reported in the literature. It required a three-step synthesis using the literature method (reaction sequence: bis-allylic chlorination, nucleophilic displacement with OAc$^-$ and hydrolysis of ester), with a total yield of 19% [38]. Our method provides alternative access to this key intermediate in a single step.

To further expand the usefulness of SeO$_2$-mediated allylic oxidation reaction in β-elemene analogue synthesis, compound **12**[2] was subjected to a milder condition to see if we can obtain a higher yield and better regioselectivity of the oxidation product. To our delight, with less catalyst and oxidant (0.4 equivalent of SeO$_2$ and 0.8 equivalence of TBHP), the selective installation of the hydroxyl group was achieved in moderate to good yield. Compound **13** can serve as a key intermediate for further functionalize the C-13 and C-14 position of β-elemene (Scheme 5).

Huang reported that β-elemenal (**11**) (figure 3) showed better anti-proliferation activity against several tumour cell lines than β-elemene (**1**) itself [13]. Apparently the aldehyde functional group contributes to the biological activity. Thus, compounds **2**, **8**, **9** and **10** were converted to the

---

[2]β-Elemene was subjected to allylic chlorination in NaOCl/acetic acid to obtain a mixture of compound **11** and its regioisomer (i.e. Cl-group in 14-position of β-elemene). After repeated chromatography in preparative HPLC, compound **11** was obtained in pure form.

Scheme 3. Compounds **6** and **7** were resolved through protecting group installation and deprotection process.

Scheme 4. Compounds **8** and **9** were resolved in silica gel chromatography using dichloromethane/acetone mixed solvent.


Scheme 5. Synthesis of compound **13** via SeO2-mediated oxidation reaction.

Figure 3. Structure of compound **10** and elemenal (**11**).

corresponding aldehydes **14–17** using standard oxidation conditions (pyridinium dichromate (PDC) in dichloromethane, 0°C to RT) (Scheme 6). All compounds were characterized by ^{1}H NMR. Undoubtedly, compounds **14–17** can serve as key intermediates in further functionalization of β-elemene.

All new compounds and β-elemene were subjected to cell proliferation inhibition assay against two tumour cell lines: A549 and U-87MG. The results will be discussed below.

Scheme 6. Synthesis of β-elemene derivatives via PDC-mediated oxidation reaction.

Table 1. Inhibition of cell proliferation against A549 and U-87MG cell lines.[a]

Compound	A549 (IC_{50}, μM)[b]	U-87 (IC_{50}, μM)[b]
β-elemene (**1**)[c]	>300	>300
2	>100	>100
3	>100	>100
6	87.23 ± 0.2	32.92 ± 0.3
7	44.57 ± 0.1	14.31 ± 0.4
8	>100	>100
9	>100	>100
10	>100	>100
13	41.24 ± 0.5	40.35 ± 0.2
14	>100	>100
15	45.28 ± 0.3	25.45 ± 0.1
16	91.44 ± 0.2	>100
17	9.34 ± 0.1	2.83 ± 0.4
STS[d]	0.021 ± 0.003	0.230 ± 0.01

[a]IC_{50} (μM): inhibitory concentration of 50% cell growth was calculated through a nonlinear fit-curve (log of compound concentration versus normalized response—variable slope).
[b]Data are presented as the means ± s.d. of three independent experiments. $p < 0.05$.
[c]The material tested here contains 78% of β-elemene, which is the same batch used in the experimental section.
[d]STS (staurosporine) was used as the positive control.

The β-elemene derivatives obtained above were assessed in anti-proliferation assay against A549 and U-87MG cell lines. The activity of some representative compounds is shown in table 1. Compounds **6**, **7**, **11**, **15** and **17** showed improved inhibitory activities than β-elemene. It is interesting to note that all the compounds showing better biological activities possess an aldehyde functional group. The reason for such phenomenon is currently being investigated in our laboratory.

3. Experimental

Typical procedure: to a solution of β-elemene (**1**) (500 mg, 2.45 mmol, 78%) in CH_2Cl_2 (10 ml) at 0°C was added dropwise 65% aqueous tert-butyl hydroperoxide (1.7 ml, 12.21 mmol). SeO_2 (270 mg, 2.45 mmol) was added into the above mixture. Then the mixture was stirred at 0°C for 6 h. The reaction was

quenched at 0°C with saturated aqueous NaHSO$_3$ solution (15 ml). The organic layer was separated, the aqueous layer was extracted with CH$_2$Cl$_2$ (2 × 10 ml). The combined organic extracts were washed with brine (10 ml), dried over anhydrous Na$_2$SO$_4$ and concentrated under reduced pressure. The residue was purified via silica gel column chromatography (petroleum ether/ethyl acetate) to yield four fractions, with polarity from the least to the most: fraction **I** (**2** and **3**, 40 mg, 7.4%, R_f = 0.9, PE/EA = 4:1), fraction **II** (**6** and **7**, 16 mg, 2.8%, R_f = 0.7, PE/EA = 4:1), fraction **III** (**8** and **9**, 50 mg, 8.6%, R_f = 0.2, PE/EA = 4:1) and fraction **IV** (**10**, 125 mg, yield 21.6%, R_f = 0.15, PE/EA = 4:1). Fraction **I** was further purified in silica gel chromatography (petroleum ether/acetone, v/v = 10:1) to yield compounds **2** (27 mg, yield 5.0%) and **3** (9 mg, yield 1.7%). Fraction **III** was further purified in silica gel chromatography (dichloromethane/acetone, v/v = 10:1) to yield compounds **8** (27 mg, yield 4.7%) and **9** (18 mg, yield 3.1%).

2-((1R,2S,5R)-2-methyl-5-(prop-1-en-2-yl)-2-vinylcyclohexyl)prop-2-en-1-ol (**2**) [35]: colourless oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 5.77 (dd, J = 17.8, 10.5 Hz, 1H), 5.17 (q, J = 1.5 Hz, 1H), 4.96–4.92 (m, 1H), 4.90 (q, J = 1.3 Hz, 1H), 4.85–4.83 (m, 1H), 4.72 (m, 2H), 4.09–3.94 (m, 2H), 2.07–2.00 (m, 1H), 2.00–1.90 (m, 1H), 1.75 (t, J = 1.1 Hz, 3H), 1.66–1.43 (m, 6H), 1.00 (s, 3H). HRMS (ESI) calcd for C$_{15}$H$_{24}$NaO [M + Na]$^+$: 243.1719, found 243.1725.

(1S,3S,4S)-4-methyl-1,3-di(prop-1-en-2-yl)-4-vinylcyclohexan-1-ol (**3**): colourless oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 5.75 (dd, J = 17.8, 10.5 Hz, 1H), 5.06 (m, 2H), 4.93–4.90 (m, 1H), 4.88 (s, 1H), 4.83 (p, J = 1.6 Hz, 1H), 4.61 (dt, J = 1.9, 0.9 Hz, 1H), 2.06–1.85 (m, 3H), 1.81 (t, J = 1.0 Hz, 3H), 1.70 (dd, J = 1.5, 0.8 Hz, 3H), 1.67–1.28 (m, 4H), 1.07 (s, 3H). ^{13}C NMR (126 MHz, CDCl$_3$) δ 149.69, 146.62, 146.47, 113.35, 112.60, 110.36, 74.39, 49.64, 39.72, 37.47, 37.20, 31.77, 24.39, 18.71, 16.68. HRMS (ESI) calcd for C$_{15}$H$_{24}$NaO [M + Na]$^+$: 243.1719, found 243.1722.

(1S,2S,5R)-1-(3-hydroxyprop-1-en-2-yl)-2-methyl-5-(prop-1-en-2-yl)-2-vinylcyclohexanol (**8**): colourless oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 5.69 (dd, J = 17.7, 10.5 Hz, 1H), 5.19 (q, J = 1.4 Hz, 1H), 5.07 (m, 2H), 4.97–4.91 (m, 1H), 4.89 (d, J = 6.9 Hz, 2H), 4.09–3.86 (m, 2H), 2.08–1.99 (m, 2H), 1.98–1.85 (m, 2H), 1.81 (d, J = 1.2 Hz, 3H), 1.72 (td, J = 13.8, 3.9 Hz, 1H), 1.47 (td, J = 13.9, 3.6 Hz, 1H), 1.34 (dt, J = 13.7, 3.7 Hz, 1H), 1.06 (s, 3H). ^{13}C NMR (126 MHz, CDCl$_3$) δ 150.53, 149.08, 146.29, 113.60, 111.67, 111.22, 74.32, 67.42, 44.90, 39.60, 37.92, 37.06, 31.60, 18.74, 16.04. HRMS (ESI) calcd for C$_{15}$H$_{24}$O$_2$ [M + H]$^+$: 236.1776, found 236.1771.

(1S,3R,4S)-3-(3-hydroxyprop-1-en-2-yl)-4-methyl-1-(prop-1-en-2-yl)-4-vinylcyclohexanol (**9**): colourless oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 5.82 (dd, J = 17.8, 10.5 Hz, 1H), 5.20 (d, J = 1.5 Hz, 1H), 5.05 (s, 1H), 4.97–4.94 (m, 1H), 4.94–4.90 (m, 1H), 4.83 (d, J = 1.4 Hz, 2H), 4.10–3.95 (m, 2H), 2.49 (dd, J = 13.3, 3.3 Hz, 1H), 1.94 (m, 2H), 1.90–1.85 (m, 1H), 1.84 (s, 3H), 1.49 (ddt, J = 16.7, 13.9, 2.9 Hz, 2H), 1.31–1.28 (m, 1H), 0.99 (s, 3H). ^{13}C NMR (126 MHz, CDCl$_3$) δ 152.04, 150.87, 149.20, 111.47, 110.91, 109.25, 73.99, 67.76, 42.14, 39.45, 37.69, 34.66, 31.02, 19.00, 15.07. HRMS (ESI) calcd for C$_{15}$H$_{24}$O$_2$ [M + H]$^+$: 236.1776, found 236.1779.

2,2′-((1R,3R,4S)-4-methyl-4-vinylcyclohexane-1,3-diyl)bis(prop-2-en-1-ol) (**10**) [36]: colourless oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 5.77 (dd, J = 17.8, 10.5 Hz, 1H), 5.17 (q, J = 1.4 Hz, 1H), 5.06 (d, J = 1.6 Hz, 1H), 4.94 (m, 2H), 4.90 (q, J = 1.4 Hz, 1H), 4.84 (s, 1H), 4.14 (s, 2H), 4.10–3.93 (m, 2H), 2.11–1.99 (m, 2H), 1.70–1.28 (m, 6H), 1.02 (s, 3H). HRMS (ESI) calcd for C$_{15}$H$_{24}$O$_2$ [M + H]$^+$: 236.1776, found 236.1772.

To a solution of fraction **II** (122 mg, 0.52 mmol), imidazole (53 mg, 0.78 mmol) and 4-dimethylaminopyridine (3 mg, 0.025 mmol) in CH$_2$Cl$_2$ (5 ml) at room temperature was added tert-butyldimethylsilyl chloride (118 mg, 0.78 mmol). The mixture was stirred at this temperature for 8 h. The reaction solution was diluted with H$_2$O (2 ml) and extracted with ethyl acetate (3 × 6 ml). The combined organic layers were washed with brine (4 ml), dried over Na$_2$SO$_4$. After filtering, the filtrate was concentrated under reduced pressure. The residue was purified via column chromatography to afford the compounds **4** (22 mg, yield 12%) and **5** (18 mg, yield: 10%).

To a solution of **5** (18 mg, 0.052 mmol) in dry THF (2 ml) was added tetrabutylammonium fluoride (0.52 ml, 0.52 mmol, 1 M solution in THF), and mixture was stirred at room temperature for 1.5 h. The reaction solution was diluted with H$_2$O (1 ml). The THF was evaporated under reduced pressure and the residue was extracted with ethyl acetate (3 × 5 ml). The combined organic layers were washed with saturated brine (3 ml), dried over Na$_2$SO$_4$. After filtering, the filtrate was concentrated under reduced pressure. The residue was purified via column chromatography to afford the compound **7** (9 mg, yield 75%). ^{1}H NMR (500 MHz, CDCl$_3$) δ 9.52 (s, 1H), 6.29 (d, J = 1.1 Hz, 1H), 5.99 (s, 1H), 5.78 (dd, J = 17.8, 10.5 Hz, 1H), 5.17 (d, J = 1.4 Hz, 1H), 4.97–4.88 (m, 2H), 4.82 (s, 1H), 4.11–3.91 (m, 2H), 2.56 (dq, J = 11.8, 7.2, 5.8 Hz, 1H), 2.13–2.07 (m, 1H), 1.67–1.61 (m, 3H), 1.61–1.55 (m, 2H), 1.53–1.45 (m, 1H), 1.03 (s, 3H). ^{13}C NMR (126 MHz, CDCl$_3$) δ 194.51, 154.57, 151.12, 149.31, 132.99, 111.01, 110.95, 67.37, 47.82, 39.58, 39.49, 36.56, 33.17, 26.61, 16.04. HRMS (ESI) calcd for C$_{15}$H$_{22}$O$_2$ [M + H]$^+$: 234.1620, found 234.1628.

Using the procedure above, compound **6** (12 mg, yield 85%) was prepared from compound **4** (22 mg, 0.062 mmol). ^{1}H NMR (500 MHz, CDCl$_3$) δ 9.39 (s, 1H), 6.15 (s, 1H), 6.04 (s, 1H), 5.65 (dd, $J = 17.4$, 10.8 Hz, 1H), 5.07 (d, $J = 1.4$ Hz, 1H), 4.95 (t, $J = 1.2$ Hz, 1H), 4.85–4.70 (m, 2H), 4.13 (d, $J = 1.2$ Hz, 2H), 2.89 (dd, $J = 13.1$, 3.3 Hz, 1H), 2.18–2.08 (m, 1H), 1.73–1.66 (m, 1H), 1.66–1.55 (m, 2H), 1.54–1.49 (m, 2H), 1.28 (m, 1H), 0.95 (s, 3H). ^{13}C NMR (126 MHz, CDCl$_3$) δ 194.40, 153.34, 151.94, 148.78, 135.12, 110.69, 108.27, 65.21, 41.31, 41.29, 39.53, 39.40, 32.60, 27.12, 14.93. HRMS (ESI) calcd for C$_{15}$H$_{22}$O$_2$ [M + H]$^+$: 234.1620, found 234.1627.

To a stirred solution of compound **2** (50 mg, 0.23 mmol) in CH$_2$Cl$_2$ (5 ml) was added PDC (129 mg, 0.34 mmol) at 0°C. The solution was sealed and stirred at 0°C for 1 h, then at room temperature for 12 h. The precipitate was filtered and washed with CH$_2$Cl$_2$. The filtrate was evaporated under reduced pressure. The residue was purified via column chromatography to afford compound **14** [37] (20 mg, yield 40%). ^{1}H NMR (400 MHz, CDCl$_3$) δ 9.32 (s, 1H), 6.08 (s, 1H), 5.97 (s, 1H), 5.59 (dd, $J = 17.4$, 10.8 Hz, 1H), 4.70 (dd, $J = 36$, 1.4 Hz, 1H), 4.71 (t, $J = 1.6$ Hz, 1H), 4.65–4.63 (m, 2H), 2.82 (dd, $J = 13.0$, 3.4 Hz, 1H), 2.10–0.93 (m, 7H), 1.67 (d, $J = 1.2$ Hz, 3H), 0.87 (s, 3H). ^{13}C NMR (126 MHz, CDCl$_3$) δ 194.48, 152.15, 149.91, 148.97, 135.06, 110.56, 108.51, 45.35, 41.20, 39.55, 39.37, 32.16, 26.65, 21.10, 14.92. HRMS (ESI) calcd for C$_{15}$H$_{22}$O [M + H]$^+$: 218.1671, found 218.1676.

Compounds **15**, **16**, **17** were prepared by following the same procedure as those described for **14**.

2-((1R,2S,5S)-5-hydroxy-2-methyl-5-(prop-1-en-2-yl)-2-vinylcyclohexyl)acrylaldehyde 15 (yield 38.7%): colourless oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 9.40 (s, 1H), 6.13 (s, 1H), 6.06 (s, 1H), 5.72 (dd, $J = 17.5$, 10.8 Hz, 1H), 5.05 (dd, $J = 1.5$, 0.8 Hz, 1H), 4.85–4.75 (m, 3H), 3.36 (dd, $J = 13.6$, 3.4 Hz, 1H), 2.02 (td, $J = 13.6$, 4.9 Hz, 2H), 1.90–1.82 (m, 1H), 1.85 (dd, $J = 1.4$, 0.7 Hz, 3H), 1.59–1.51 (m, 1H), 1.41–1.27 (m, 3H), 0.93 (s, 3H). ^{13}C NMR (126 MHz, CDCl$_3$) δ 194.88, 165.86, 145.34, 142.32, 127.42, 110.80, 109.34, 83.42, 39.51, 35.90, 31.88, 29.70, 29.49, 29.14, 14.15. HRMS (ESI) calcd for C$_{15}$H$_{22}$O$_2$ [M + H]$^+$: 234.1620, found 234.1624.

2-((1R,2S,5R)-5-hydroxy-2-methyl-5-(prop-1-en-2-yl)-2-vinylcyclohexyl)acrylaldehyde 16 (yield 36%): colourless oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 9.29 (s, 1H), 7.54 (s, 1H), 5.88 (ddd, $J = 18.0$, 10.7, 1.0 Hz, 1H), 5.15 (d, $J = 1.9$ Hz, 1H), 5.13–5.10 (m, 1H), 5.00 (s, 1H), 4.90 (t, $J = 1.5$ Hz, 1H), 2.87 (s, 1H), 2.09 (dd, $J = 13.3$, 2.7 Hz, 1H), 1.88–1.81 (m, 3H), 1.80 (t, $J = 1.0$ Hz, 3H), 1.61 (dt, $J = 3.9$, 1.9 Hz, 1H), 1.46 (ddd, $J = 13.4$, 3.8, 1.9 Hz, 1H), 1.40–1.32 (m, 1H), 0.85 (s, 3H). ^{13}C NMR (126 MHz, CDCl$_3$) δ 189.26, 167.08, 146.91, 144.95, 121.31, 112.93, 111.21, 83.42, 40.80, 33.33, 32.69, 29.86, 29.70, 28.54, 18.63. HRMS (ESI) calcd for C$_{15}$H$_{22}$O$_2$ [M + H]$^+$: 234.1620, found 234.1627.

2,2′-((1R,3R,4S)-4-methyl-4-vinylcyclohexane-1,3-diyl)diacrylaldehyde 17 (yield 80%): colourless oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 9.53 (s, 1H), 9.38 (s, 1H), 6.29 (d, $J = 1.0$ Hz, 1H), 6.12 (s, 1H), 6.03 (s, 1H), 6.00 (s, 1H), 5.67 (dd, $J = 17.4$, 10.8 Hz, 1H), 4.84–4.73 (m, 2H), 2.95 (dd, $J = 13.1$, 3.3 Hz, 1H), 2.67–2.57 (m, 1H), 1.73–1.21 (m, 6H), 0.97 (s, 3H). ^{13}C NMR (126 MHz, CDCl$_3$) δ 194.36, 194.21, 154.35, 151.71, 148.65, 135.04, 133.11, 110.78, 41.35, 39.17, 36.77, 31.73, 29.70, 26.46, 18.45. HRMS (ESI) calcd for C$_{15}$H$_{20}$O$_2$ [M + H]$^+$: 232.1463, found 232.1469.

To a solution of **12** (100 mg, 0.42 mmol) in CH$_2$Cl$_2$ (3 ml) at 0°C was added dropwise 65% aqueous tert-butyl hydroperoxide (0.047 ml, 0.336 mmol). SeO$_2$ (19 mg, 0.168 mmol) was added into the above mixture. The mixture was stirred at 0°C for 6 h. The reaction was quenched at 0°C with saturated aqueous NaHSO$_3$ solution (3 ml). The organic layer was separated, the aqueous layer was extracted with CH$_2$Cl$_2$ (2 × 3 ml). The combined organic extracts were washed with brine (3 ml), dried over anhydrous Na$_2$SO$_4$ and concentrated under reduced pressure. The residue was purified via silica gel column chromatography (petroleum ether/ethyl acetate) to afford compound **13** (60 mg, yield 56%). ^{1}H NMR (500 MHz, CDCl$_3$) δ 5.77 (dd, $J = 17.7$, 10.5 Hz, 1H), 5.21–5.14 (m, 2H), 5.04 (d, $J = 1.1$ Hz, 1H), 4.97–4.90 (m, 2H), 4.84 (s, 1H), 4.09 (d, $J = 0.9$ Hz, 2H), 4.09–3.94 (m, 2H), 2.28–2.17 (m, 1H), 2.07 (dd, $J = 12.3$, 3.9 Hz, 1H), 1.77–1.69 (m, 1H), 1.69–1.57 (m, 1H), 1.57–1.44 (m, 4H), 1.01 (s, 3H). ^{13}C NMR (126 MHz, CDCl$_3$) δ 151.20, 149.59, 149.35, 113.27, 111.22, 110.94, 67.48, 47.90, 47.69, 41.07, 39.65, 39.60, 33.64, 27.00, 16.01. HRMS (ESI) calcd for C$_{15}$H$_{23}$ClO [M + H]$^+$: 254.1437, found 254.1439.

4. Biological assay

4.1. Materials

Cell Titer-Glo luminescent cell viability assay kits (cat. no. G7573, lot. no. 0000365004) were obtained from Promega; MEM (cat. no. 11095-080; lot. no. 2053121), 0.25% Trypsine-EDTA (cat. no. 25200-072, lot. no. 2042303) and F-12 K (cat. no. 21127-022; lot. no. 2085296) were obtained from Invitrogen; FBS

(Biological Industries, cat. no. 04-002-1A, lot. no. 1841929); Penicillin-Streptomycin solution cat. no. SV30010, lot. no. J180029) was obtained from Hyclone; Glutamax (cat. no. 35050-061; lot no. 2085268) was obtained from Gibco; DMSO (cat. no. 276855-1 L, lot. no. STBD7938 V) was obtained from Sigma; 96-well plate, white wall with clear bottom, tissue culture-treated (cat. no. CLS3903; lot. no. 25116010) was obtained from Corning.

4.2. Methods

The suspension of specific tumour cells was adjusted to 5×10^4 ml^{-1} or 2×10^4 ml^{-1} with DMEM + 2 mm glutamine + 10% FBS medium. Add 100 µl cell suspension to 96-well cell culture plate, and the final cell concentration is 5000 cells well^{-1} (72 h). DMSO was used to dissolve the compound to be tested as 100 mM storage solution. The final concentration of 200× compound was prepared with storage solution and DMSO, and the gradient dilutions of 3× series were prepared, and then diluted 20 times with culture medium respectively. Finally, 10 µl corresponding 10-fold solution was added to each cell hole, and each drug concentration was in duplicate holes. The final concentrations of each compound were 300 µM, 100 µM, 33.33 µM, 11.11 µM, 3.704 µM, 1.235 µM and 0.412 µM, and the final concentration of DMSO per pore was 0.5%. Incubate in a 37°C, 5% CO_2 incubator for 72 h. After 72 h of drug treatment, add 100 µl celltiter glo detection reagent into each hole according to the CTG operation instructions, melt and balance the CTG solution to room temperature in advance, mix it with microporous plate shaker for 2 min, place it at room temperature for 10 min, and the luminescence is recorded with a luminometer. The cell survival rate was calculated by the formula: $(V_{sample} - V_{blank})/(V_{vehicle\ control} - V_{blank}) \times 100\%$. V_{sample} is the reading of the drug treatment group, $V_{vehicle\ control}$ is the average of the solvent control group, and V_{blank} is the average of the blank control hole. By using graphpad prism 5.0 software, a nonlinear regression model was used to draw the S-type dose survival curve and calculate the IC$_{50}$ value.

5. Conclusion

SeO$_2$-mediated allylic oxidation reaction was first applied to β-elemene, a substrate bearing three carbon-carbon double bonds and several allylic hydrogen atoms, and was discovered to produce seven derivatives of β-elemene in a single step. Several additional analogues of β-elemene were further synthesized and found to display better inhibitory activities against A549 and U-87 cell proliferation. All compounds in this article can serve as key intermediates for further derivatization of β-elemene. Our approaches represent the first success to introduce functional groups onto the cyclohexyl ring, a challenging task unexplored before.

References

1. Lim CB, Ky N, Ng HM, Hamza MS, Zhao Y. 2010 *Curcuma wenyujin* extract induces apoptosis and inhibits proliferation of human cervical cancer cells *in vitro* and *in vivo*. *Integr. Cancer Ther.* **9**, 36–49. (doi:10.1177/1534735409359773)

2. Lu JJ, Dang YY, Huang M, Xu WS, Chen XP, Wang YT. 2012 Anti-cancer properties of terpenoids isolated from *Rhizoma Curcumae* – a

review. *J. Ethnopharmacol.* **143**, 406–411. (doi:10.1016/j.jep.2012.07.009)

3. Yao YQ, Ding X, Jia YC, Huang CX, Wang YZ, Xu YH. 2008 Anti-tumor effect of β-elemene in glioblastoma cells depends on p38 MAPK activation. *Cancer Lett.* **264**, 127–134. (doi:10.1016/j.canlet.2008.01.049)

4. Zhou YY et al. 2015 Elemene, the essential oil of *Curcuma wenyujin*, inhibits osteogenic differentiation in ankylosing spondylitis. *Joint Bone Spine* **82**, 100–103. (doi:10.1016/j.jbspin.2014.05.004)

5. Zhu JJ, Lower-Nedza AD, Hong M, Jiec S, Wang ZM, Dong YM, Tschiggerl C, Bucar F, Brantner AH. 2013 Chemical composition and antimicrobial activity of three essential oils from *Curcuma wenyujin*. *Nat. Prod. Commun.* **8**, 523–526. (doi:10.1177/1934578X1300800430)

6. Thang TD, Dai DN, Luong NX, Ogunwande IA. 2014 Constituents of essential oils from the leaves, stem barks and resins of *Canarium parvum* Leen., and *Canarium tramdenanum* Dai et Yakovl. (Burseracea) grown in Vietnam. *Nat. Prod. Res.* **28**, 461–466. (doi:10.1080/14786419.2013.873435)

7. Adio AM. 2009 (−)-*trans*-β-elemene and related compounds: occurrence, synthesis, and anticancer activity. *Tetrahedron* **27**, 5145–5159. (doi:10.1016/j.tet.2009.04.062)

8. Zhai BT et al. 2018 Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy. *Int. J. Nanomed.* **13**, 6279–6296. (doi:10.2147/ijn.S174527)

9. Zhang S, Zhou P, Duan H, Yuan H. 2010 Progress of β-elemene and its derivatives. *Chemistry (Easton).* **73**, 499–505. (doi:10.14159/j.cnki.0441-3776.2010.06.010)

10. Zhai BT et al. 2019 Molecular targets of β-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: a review. *Biomed. Pharmacother.* **114**, 108812. (doi:10.1016/j.biopha.2019.108812)

11. Chang ZW, Gao M, Zhang WJ, Song LJ, Jia YX, Qin YR. 2017 Beta-elemene treatment is associated with improved outcomes of patients with esophageal squamous cell carcinoma. *Surgical Oncol.-Oxford* **26**, 333–337. (doi:10.1016/j.suronc.2017.07.002)

12. Yan B et al. 2013 β-elemene-attenuated tumor angiogenesis by targeting Notch-1 in gastric cancer stem-Like cells. *Evid. Based Complement. Alternat. Med.* 2013 1–12. (doi:10.1155/2013/268468)

13. Huang L. 2006 Synthesis of (-)-β-elemene, (-)-β-elemenal, (-)-β-elemenol, (-)-β-elemene fluoride and their analogs for use in anticancer pharmaceutical compositions. Patent WO2006016912A2.

14. Deng M et al. 2019 β-Elemene inhibits peritoneal metastasis of gastric cancer cells by modulating FAK/Claudin-1 signaling. *Phytother. Res.* **33**, 2448–2456. (doi:10.1002/ptr.6436)

15. Long J, Liu Z, Hui L. 2019 Anti-tumor effect and mechanistic study of elemene on pancreatic carcinoma. *BMC Complement. Altern. Med.* **19**, 133. (doi:10.1186/s12906-019-2544-2)

16. Wu D, Lv D, Zhang T, Guo L, Ma F, Zhang C, Lv G, Huang L. 2019 Antitumor effects of β-elemene via targeting the phosphorylation of insulin receptor. *Endocr.-Relat. Cancer* **26**, 187–199. (doi:10.1530/erc-18-0370)

17. Lu MX, Wang XP, Bu ZS, Lv LQ, Tong SQ. 2017 Silver ion coordination countercurrent chromatography: separation of beta-elemene from the volatile oil of *Curcumae Rhizoma*. *J. Sep. Sci.* **40**, 3740–3747. (doi:10.1002/jssc.201700399)

18. Genčić MS, Radulović NS. 2015 Lanthanide-induced shift reagents enable the structural elucidation of natural products in inseparable complex mixtures – the case of elemenal from *Inula helenium* L. (Asteraceae). *RSC Advs.* **5**, 72 670–72 682. (doi:10.1039/C5RA13109J)

19. Li QDQ, Wang GD, Zhang MC, Cuff CF, Huang L, Reed E. 2009 β-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. *Oncol. Rep.* **22**, 161–170. (doi:10.3892/or_00000420)

20. Zhu TZ, Zhao YS, Zhang JN, Li LJ, Zou LJ, Yao YQ, Xu YH. 2011 β-Elemene inhibits proliferation of human glioblastoma cells and causes cell-cycle G0/G1 arrest via mutually compensatory activation of MKK3 and MKK6. *Int. J. Oncol.* **38**, 419–426. (doi:10.3892/ijo.2010.855)

21. Barrero AF, Herrador MM, Moral JFQD, Arteaga P, Catalán JV. 2011 Efficient synthesis of the anticancer β-elemene and other bioactive elemanes from sustainable germacrone. *Org. Biomol. Chem.* **9**, 1118–1125. (doi:10.1039/C0OB00467G)

22. Xu LY, Tao SJ, Wang XM, Yu ZY, Wang MW, Chen D, Jing YK, Dong JH. 2006 The synthesis and anti-proliferative effects of β-elemene derivatives with mTOR inhibition activity. *Biorg. Med. Chem.* **14**, 5351–5356. (doi:10.1016/j.bmc.2006.03.041)

23. Sun YH, Liu GF, Zhang YQ, Zhu H, Ren YF, Shen YM. 2009 Synthesis and *in vitro* anti-proliferative activity of β-elemene monosubstituted derivatives in HeLa cells mediated through arrest of cell cycle at the G1 phase. *Biorg. Med. Chem.* **17**, 1118–1124. (doi:10.1016/j.bmc.2008.12.040)

24. Chen JC et al. 2017 Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3 K/Akt pathway. *Eur. J. Med. Chem.* **135**, 414–423. (doi:10.1016/j.ejmech.2017.04.045)

25. Chen J et al. 2017 Antioxidant properties of novel dimers derived from natural β-elemene through inhibiting H2O2-induced apoptosis. *ACS Med. Chem. Lett.* **8**, 443–448. (doi:10.1021/acsmedchemlett.7b00035)

26. Chen J, Wang T, Xu S, Lin A, Yao H, Xie W, Zhu Z, Xu J. 2017 Novel hybrids of natural β-elemene bearing isopropanolamine moieties: synthesis, enhanced anticancer profile, and improved aqueous solubility. *Fitoterapia* **120**, 117–125. (doi:10.1016/j.fitote.2017.05.002)

27. Thomas AF, Vial C, Ozainne M, Ohloff G. 1973 The oxidation of the double bonds of β-elemene. *Helv. Chim. Acta.* **56**, 2270–2279. (doi:10.1002/hlca.19730560715)

28. Umbreit MA, Sharpless KB. 1977 Allylic oxidation of olefins by catalytic and stoichiometric selenium dioxide with tert-butyl hydroperoxide. *J. Am. Chem. Soc.* **99**, 5526–5528. (doi:10.1021/ja00458a072)

29. Młochowski J, Wójtowicz-Młochowska H. 2015 Developments in synthetic application of selenium(IV) oxide and organoselenium compounds as oxygen donors and oxygen-transfer agents. *Molecules* **20**, 10 205–10 243. (doi:10.3390/molecules200610205)

30. Patel RM, Puranik VG, Argade NP. 2011 Regio- and stereoselective selenium dioxide allylic oxidation of (E)-dialkyl alkylidenesuccinates to (Z)-allylic alcohols: synthesis of natural and unnatural butenolides. *Org. Biomol. Chem.* **9**, 6312. (doi:10.1039/C10B05709J)

31. Uttaro JP, Audran G, Palombo E, Monti H. 2003 First enantioselective synthesis and absolute stereochemistry assignment of new monocyclic sesquiterpenes from *Artemisia chamaemelifolia*. *J. Org. Chem.* **68**, 5407–5410. (doi:10.1021/jo034424y)

32. Singleton DA, Hang C. 2000 Isotope effects and the mechanism of allylic hydroxylation of alkenes with selenium dioxide. *J. Org. Chem.* **65**, 7554–7560. (doi:10.1021/jo000922k)

33. Sharpless K, Hori T, Truesdale L, Dietrich C. 1976 Allylic amination of olefins and acetylenes by imido selenium compounds. *J. Am. Chem. Soc.* **98**, 269–271.

34. Bai R, Jie X, Salgado E, Sun J, Zhu Y, Pickel T, Xie Y, Chen J, Xu J. 2018 Rational design, synthesis and biological evaluation of novel derivatives based on *in vivo* metabolism of natural product β-elemene. *Lett. Drug. Des. Discov.* **15**, 905–912. (doi:10.2174/1570180814666171108093021)

35. Chen JC, Duan WL, Bai RR, Yao HQ, Shang J, Xu JY. 2014 Design, synthesis and antioxidant activity evaluation of novel beta-elemene derivatives. *Bioorg. Med. Chem. Lett.* **24**, 3407–3411. (doi:10.1016/j.bmcl.2014.05.078)

36. Hu J, Jia W, Yang L, Li Z. 1990 The NMR study of β-elemene derivates. *Chin. J. Magn. Reson.* **7**, 339–344.

37. Harrison LJ, Becker H, Connolly JD, Rycroft DS. 1992 Two elemane sesquiterpenoids from the liverwort *Plagiochasma rupestre*. *J. Chem. Res., Synop.* **2**, 74–75.

38. Jia WM, Yang LM, Li ZH, Hu JH. 1991 Synthesis of the antitumor β-elemene derivatives. *Chin. J. Inorg. Chem.* **11**, 608–610.

39. Ding DY, Hu JH. 1991 UV study on the ways of interactions of drugs with DNA—effects of cddp, Cp2TiCl2 and DHE on alkali denaturation of DNA. *Spectrosc. Spect. Anal.* **11**, 7–10.

40. He X, Zhuo X-T, Gao Y, Bai R, Ye X-Y, Xie T. 2020 Data from: β-Elemene derivatives produced from SeO2-mediated oxidation reaction. Dryad Digital Repository. (doi:10.5061/dryad.cnp5hqc1w)